CJCharles W. Joyce

Charles W. Joyce

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Charles W. Joyce has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • H. Bryan Brewer

    From the Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md

    2 shared publications
  • Silvia Santamarina-Fojo

    From the Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md

    2 shared publications
  • Alan T. Remaley

    Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892; ‡The Jackson Laboratory, Bar Harbor, ME 04609; and §Department d'Atherosclerosis, Pasteur Institute, Lille 59019, France

    1 shared publication
  • Beverly Paigen

    Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892; ‡The Jackson Laboratory, Bar Harbor, ME 04609; and §Department d'Atherosclerosis, Pasteur Institute, Lille 59019, France

    1 shared publication
  • Boris L. Vaisman

    Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892; ‡The Jackson Laboratory, Bar Harbor, ME 04609; and §Department d'Atherosclerosis, Pasteur Institute, Lille 59019, France

    1 shared publication
  • Donald S. Fredrickson

    Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892; ‡The Jackson Laboratory, Bar Harbor, ME 04609; and §Department d'Atherosclerosis, Pasteur Institute, Lille 59019, France

    1 shared publication

Latest Publications

  • Open Access

    Study of ABCA1 Function in Transgenic Mice

    by Charles Joyce, Lita Freeman, H. Bryan Brewer, Silvia Santamarina-Fojo

    The ATP-binding cassette transporter A1 (ABCA1), identified in 1999 as the gene defective in Tangier disease, promotes efflux of cellular cholesterol from macrophages and other peripheral tissues to apolipoprotein acceptors. These ABCA1-mediated processes are anticipated to have antiatherogenic properties, prompting the development of pharmacological agents that increase ABCA1 gene expression as well as the establishment of ABCA1-transgenic mouse lines. Preliminary studies of ABCA1-Tg mice seem to validate the selection of this transporter as a therapeutic target for the treatment of low HDL syndromes and cardiovascular disease but have also raised new questions regarding the function of ABCA1. In particular, the relative contribution of hepatic and peripheral ABCA1 to plasma HDL levels and to reverse cholesterol transport, as well as the potential role of ABCA1 in modulating the plasma concentrations of the apolipoprotein B–containing lipoproteins and protecting against atherosclerosis, seem to be promising areas of investigation. The present review summarizes the most recent studies and discusses insights provided by these transgenic mouse models.


  • Open Access

    The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice

    by Charles W. Joyce, Marcelo J. A. Amar, Gilles Lambert, Boris L. Vaisman, Beverly Paigen, Jamila Najib-Fruchart, Robert F. Hoyt, Edward D. Neufeld, Alan T. Remaley, Donald S. Fredrickson, et al.

    Identification of mutations in the ABCA1 transporter (ABCA1) as the genetic defect in Tangier disease has generated interest in modulating atherogenic risk by enhancing ABCA1 gene expression. To investigate the role of ABCA1 in atherogenesis, we analyzed diet-induced atherosclerosis in transgenic mice overexpressing human ABCA1 (hABCA1-Tg) and spontaneous lesion formation in hABCA1-Tg × apoE-knockout (KO) mice. Overexpression of hABCA1 in C57BL/6 mice resulted in a unique anti-atherogenic profile characterized by decreased plasma cholesterol (63%), cholesteryl ester (63%), free cholesterol (67%), non-high density lipoprotein (HDL)-cholesterol (53%), and apolipoprotein (apo) B (64%) but markedly increased HDL-cholesterol (2.8-fold), apoA-I (2.2-fold), and apoE (2.8-fold) levels. These beneficial changes in the lipid profile led to significantly lower (65%) aortic atherosclerosis in hABCA1-Tg mice. In marked contrast, ABCA1 overexpression had a minimal effect on the plasma lipid profile of apoE-KO mice and resulted in a 2- to 2.6-fold increase in aortic lesion area. These combined results indicate that overexpression of ABCA1 in C57BL/6 mice on a high cholesterol diet results in an atheroprotective lipoprotein profile and decreased atherosclerosis, and thus provide previously undocumented in vivo evidence of an anti-atherogenic role for the ABCA1 transporter. In contrast, overexpression of ABCA1 in an apoE-KO background led to increased atherosclerosis, further substantiating the important role of apoE in macrophage cholesterol metabolism and atherogenesis. In summary, these results establish that, in the presence of apoE, overexpression of ABCA1 modulates HDL as well as apoB-containing lipoprotein metabolism and reduces atherosclerosis in vivo , and indicate that pharmacological agents that will increase ABCA1 expression may reduce atherogenic risk in humans.